Zimmer Biomet Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Zimmer Biomet Holdings is Ivan Tornos, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.19M, bestaande uit 9.5% salaris en 90.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.013% van de aandelen van het bedrijf, ter waarde CHF 2.59M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.7 jaar en 6.3 jaar.

Belangrijke informatie

Ivan Tornos

Algemeen directeur

US$10.2m

Totale compensatie

Percentage CEO-salaris	9.5%
Dienstverband CEO	3.7yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	3.7yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ivan Tornos's beloning veranderd ten opzichte van Zimmer Biomet Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$997m
Mar 31 2024	n/a	n/a	US$964m
Dec 31 2023	US$10m	US$969k	US$1b
Sep 30 2023	n/a	n/a	US$474m
Jun 30 2023	n/a	n/a	US$506m
Mar 31 2023	n/a	n/a	US$450m
Dec 31 2022	US$6m	US$823k	US$290m
Sep 30 2022	n/a	n/a	US$366m
Jun 30 2022	n/a	n/a	US$334m
Mar 31 2022	n/a	n/a	US$325m
Dec 31 2021	US$5m	US$731k	US$445m
Sep 30 2021	n/a	n/a	US$834m
Jun 30 2021	n/a	n/a	US$914m
Mar 31 2021	n/a	n/a	US$563m
Dec 31 2020	US$4m	US$730k	-US$11m
Sep 30 2020	n/a	n/a	-US$152m
Jun 30 2020	n/a	n/a	US$37m
Mar 31 2020	n/a	n/a	US$377m
Dec 31 2019	US$4m	US$700k	US$1b
Sep 30 2019	n/a	n/a	-US$90m
Jun 30 2019	n/a	n/a	-US$359m
Mar 31 2019	n/a	n/a	-US$308m
Dec 31 2018	US$4m	US$113k	-US$379m

Compensatie versus markt: De totale vergoeding ($USD 10.19M ) Ivan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.77M ).

Compensatie versus inkomsten: De vergoeding van Ivan is het afgelopen jaar met meer dan 20% gestegen.

CEO

Ivan Tornos (49 yo)

3.7yrs

Tenure

US$10,191,476

Compensatie

Mr. Ivan Tornos serves as Independent External Director at PHC Holdings Corporation since September 03, 2021. He joined PHC Holdings Corporation on September 03, 2021. Mr. Tornos serves as Chief Operating...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ivan Tornos	COO, President	3.7yrs	US$10.19m	0.013% CHF 2.6m
Suketu Upadhyay	CFO and Executive VP of Finance	5.3yrs	US$10.38m	0.015% CHF 2.9m
Chad Phipps	Senior VP	17.5yrs	US$2.87m	0.025% CHF 4.8m
Sang Yi	President of Asia Pacific	9.4yrs	US$3.38m	0.0027% CHF 515.2k
Wilfred van Zuilen	Group President of Europe	3.4yrs	US$3.42m	0.0046% CHF 895.2k
Paul Stellato	VP, Controller & Chief Accounting Officer	2.5yrs	geen gegevens	0.00069% CHF 133.1k
Shaun Braun	Senior VP & Chief Information and Technology Officer	less than a year	geen gegevens	geen gegevens
Rachel Ellingson	Senior VP & Chief Administrative Officer	less than a year	geen gegevens	0.0034% CHF 663.7k
David DeMartino	Senior VP of Investor Relations	less than a year	geen gegevens	geen gegevens
Angela Main	Senior VP	9.4yrs	geen gegevens	geen gegevens
Lori Winkler	Senior VP & Chief Human Resources Officer	3.8yrs	geen gegevens	0.0017% CHF 324.1k
David Kunz	Senior Vice President of Global Quality & Regulatory Affairs	7.3yrs	geen gegevens	geen gegevens

3.7yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ZBH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ivan Tornos	COO, President	1.3yrs	US$10.19m	0.013% CHF 2.6m
Christopher Begley	Independent Chairman of the Board	12.3yrs	US$409.38k	0.0018% CHF 343.4k
Betsy Bernard	Independent Director	15.8yrs	US$340.26k	0.0027% CHF 511.3k
Robert Hagemann	Independent Director	16.7yrs	US$358.20k	0.0020% CHF 387.8k
Arthur Higgins	Independent Director	17.8yrs	US$347.75k	0.0017% CHF 329.9k
Louis Shapiro	Director	less than a year	geen gegevens	geen gegevens
Maria Hilado	Independent Director	6.3yrs	US$314.44k	0.00083% CHF 160.1k
Michael Farrell	Independent Director	9.9yrs	US$342.52k	0.0010% CHF 192.9k
Devdatt Kurdikar	Director	less than a year	geen gegevens	geen gegevens
Sreelakshmi Kolli	Independent Director	3.8yrs	US$382.35k	0.00050% CHF 96.5k
Syed Jafry	Independent Director	6.3yrs	US$367.52k	0.0020% CHF 393.6k

6.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ZBH wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Zimmer Biomet Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Zimmer Biomet Holdings, Inc. Appoints Arnold Schwarzenegger as Chief Movement Officer

Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations

Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors

President of Asia Pacific recently sold CHF1.3m worth of stock

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Recent updates

Zimmer Biomet Holdings, Inc. Appoints Arnold Schwarzenegger as Chief Movement Officer

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Ending December 31, 2024

Third quarter 2024 earnings released: EPS: US$1.23 (vs US$0.78 in 3Q 2023)

Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting

Zimmer Biomet Holdings, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc. Appoints David Demartino as Senior Vice President, Investor Relations

Second quarter dividend of US$0.24 announced

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024, Payable on or About October 31, 2024

Second quarter 2024 earnings released: EPS: US$1.18 (vs US$1.01 in 2Q 2023)

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2024

Zimmer Biomet Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Zimmer Biomet Holdings, Inc. Appoints Devdatt Kurdikar to its Board of Directors

Upcoming dividend of US$0.24 per share

President of Asia Pacific recently sold CHF1.3m worth of stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announces an Equity Buyback for $2,000 million worth of its shares.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announces an Equity Buyback for $2,000 million worth of its shares.

First quarter dividend of US$0.24 announced

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2024, Payable on or About July 31, 2024

Zimmer Biomet Holdings, Inc. Reiterates Financial Guidance for Current Full-Year 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: US$0.84 (vs US$1.11 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Zimmer Biomet Holdings, Inc. to Report Q1, 2024 Results on May 02, 2024

Zimmer Biomet Holdings, Inc., Annual General Meeting, May 10, 2024

Upcoming dividend of US$0.24 per share

Full year 2023 earnings released: EPS: US$4.91 (vs US$1.39 in FY 2022)

Fourth quarter dividend of US$0.24 announced

Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration (FDA) 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery

Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024

Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting

Full year 2023 earnings released: EPS: US$4.91 (vs US$1.39 in FY 2022)

Zimmer Biomet Holdings, Inc. Provides Earnings Guidance for the Full Year 2024

Zimmer Biomet Holdings, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Zimmer Biomet Holdings, Inc. Announces Appointment of Louis A. Shapiro to Board of Directors

Upcoming dividend of US$0.24 per share at 0.8% yield

Zimmer Biomet Holdings, Inc. Approves Cash Dividend for the Fourth Quarter of 2023, Payable on or About January 31, 2024

Third quarter 2023 earnings released: EPS: US$0.78 (vs US$0.93 in 3Q 2022)

Zimmer Biomet Holdings, Inc. Updates Revenue Guidance for the Year Ending December 31, 2023

Zimmer Biomet Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Upcoming dividend of US$0.24 per share at 0.8% yield

Zimmer Biomet Holdings, Inc. Announces Quarterly Dividend for Third Quarter of 2023, Payable on or about October 31, 2023

Zimmer Biomet Holdings, Inc. Announces CEO Changes

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.01 (vs US$0.73 in 2Q 2022)

Zimmer Biomet Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.24 per share at 0.7% yield

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2023, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.11 (vs US$0.35 in 1Q 2022)

Upcoming dividend of US$0.24 per share at 0.8% yield

Full year 2022 earnings released: EPS: US$1.39 (vs US$1.93 in FY 2021)

Zimmer Biomet Holdings, Inc. Reports Unaudited Impairment Charges for the Fourth Quarter Ended December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) entered into a definitive agreement to acquire Embody, Inc. for approximately $300 million.

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2022, Payable on or About January 31, 2023

Zimmer Biomet Holdings, Inc. Expands Persona(R) Knee System Portfolio with FDA Clearance of Persona(R) Osseoti(R) Keel Tibia for Cementless Knee Replacement

Insufficient new directors

Zimmer Biomet Holdings, Inc. Announces One-Year Data from mymobility® Clinical Study at 2022 AAHKS Annual Meeting

Third quarter 2022 earnings released: EPS: US$0.93 (vs US$0.70 in 3Q 2021)

Zimmer Biomet Holdings, Inc. Updates Financial Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc. Receives FDA Clearance for Identity(TM) Shoulder System for Shoulder Replacement

Zimmer Biomet Holdings, Inc Approves Quarterly Cash Dividend, Payable on or About October 31, 2022

Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021)

Zimmer Biomet Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2022

Zimmer Biomet Holdings, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Upcoming dividend of US$0.24 per share

Zimmer Biomet Holdings, Inc. Appoints Keri P. Mattox as Chief Communications and Administration Officer